To test the effect of Resv on breast cancer, four studies used mice where Resv showed a reducing effect in three experiments [1], [39], [40] (in chemical induced cancers, in a HER-2/neu transgenic mice model and injected Ehrlich ascites carcinoma cells), whereas Resv failed to show chemoprevention in a model where 4T1 mammary carcinoma cells were injected into the mice [41]. This evidence concerns the gene ERBB2 and breast cancer.